{"url":"https://nivawealth.com/firms/patient-square-capital-312203","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/312203","regulatoryAum":17512552081,"crd":"312203","secFileNumber":"801-120508","legalName":"Patient Square Capital, LP","displayName":"Patient Square Capital","website":"https://patientsquarecapital.com/","linkedinUrl":"https://www.linkedin.com/company/patient-square-capital","founded":null,"organization":"Delaware limited partnership","fiscalYearEnd":"December","headquarters":{"street":"2884 Sand Hill Road, Suite 100","city":"Menlo Park","state":"CA","stateName":"California","country":"United States","postalCode":"94025"},"tradeNames":[],"registration":{"secApproved":"15 March 2021","noticeFilings":null,"latestNoticeFiling":null},"staff":{"employees":97,"advisory":50,"brokerDealerReps":3,"insuranceAgents":0,"promoters":0},"aum":{"discretionary":17512552081,"discretionaryAccounts":30,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":0,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":30,"regulatoryAum":17512552081}],"fees":[],"feeNotes":[],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Patient Square Capital has custody of client assets.","otherCustodians":[],"leadership":[{"name":"Christopher Wade","title":"Chief Financial Officer and Partner","crd":"8230419"},{"name":"Carolyn Drayer-Greenwalt","title":"Chief Compliance Officer and Managing Director","crd":"7146911"},{"name":"Adam Fliss","title":"Founding Partner; Head of Strategy, Capital, Legal, and Government Affairs","crd":"6931448"},{"name":"James Momtazee","title":"Managing Partner","crd":"2539933"}],"ownership":[{"label":"Patient Square Partner Holdings, LP","detail":"Limited partner in the 75% or more ownership band and a control person, since February 2021."},{"label":"James Momtazee","detail":"Indirect owner: a limited partner of Patient Square Partner Holdings, LP in the 50% to 75% band and a control person, since February 2021. Also a managing member of Patient Square Capital Holdings, LLC in the 75% or more band and a control person, since August 2020.","parent":"Patient Square Partner Holdings, LP"},{"label":"Patient Square Capital Holdings, LLC","detail":"Indirect owner: general partner of Patient Square Partner Holdings, LP and a control person, since February 2021.","parent":"Patient Square Partner Holdings, LP"}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":2,"privateResidences":0},"listedOfficeAddresses":2,"officesByState":[{"state":"California","offices":1,"addresses":[{"street":"2884 Sand Hill Road, Suite 100","city":"Menlo Park","headquarters":true}]},{"state":"New York","offices":1,"addresses":[{"street":"767 Fifth Avenue","city":"New York"}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"650-677-8100","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[],"privateFunds":30},"sources":{"adv1FilingDate":"26 May 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/312203/PDF/312203.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Patient Square Capital have?","answer":"Patient Square Capital has 30 clients and manages $17.5 billion for them, as of May 2026.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 26 May 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Patient Square Capital offer?","answer":"Patient Square Capital provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Patient Square Capital have?","answer":"Patient Square Capital has 0 investment adviser representatives registered with state securities authorities, out of 97 employees, and 50 perform investment advisory functions. 3 are registered representatives of a broker-dealer and 0 are licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Patient Square Capital?","answer":"Patient Square Capital is owned through a holding company by James Momtazee. Its direct owner is Patient Square Partner Holdings, LP (75% or more).","source":"Form ADV Part 1A, Schedules A and B, filed 26 May 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Patient Square Capital get paid?","answer":"Patient Square Capital is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}}],"holdings":{"url":"https://nivawealth.com/firms/patient-square-capital-312203/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-12","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1819257/000181925726000005/0001819257-26-000005-index.html","totalValue":645523811,"positionCount":23,"top10Share":0.8013113291648973,"top10":[{"issuer":"ROIVANT SCIENCES LTD","titleOfClass":"SHS","cusip":"G76279101","value":283860642,"shares":8020928,"shareType":"SH","priorValue":226199502,"priorShares":8166047},{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"COM","cusip":"76155X100","value":51689280,"shares":276000,"shareType":"SH"},{"issuer":"MIRUM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"604749101","value":30496735,"shares":260500,"shareType":"SH","priorValue":21247400,"priorShares":230000},{"issuer":"ABIVAX SA","titleOfClass":"SPONSORED ADS","cusip":"00370M103","value":27518190,"shares":206500,"shareType":"SH","priorValue":13500631,"priorShares":121245},{"issuer":"BEONE MEDICINES LTD","titleOfClass":"SPONSORED ADS","cusip":"07725L102","value":25652999,"shares":90020,"shareType":"SH","priorValue":23918558,"priorShares":80542},{"issuer":"PHARVARIS N V","titleOfClass":"COM","cusip":"N69605108","value":23210407,"shares":671209,"shareType":"SH","priorValue":13927250,"priorShares":493000},{"issuer":"ARGENX SE","titleOfClass":"SPONSORED ADR","cusip":"04016X101","value":21338710,"shares":23000,"shareType":"SH","priorValue":26813320,"priorShares":36718},{"issuer":"UNITED THERAPEUTICS CORP DEL","titleOfClass":"COM","cusip":"91307C102","value":20112730,"shares":37120,"shareType":"SH"},{"issuer":"BELITE BIO INC","titleOfClass":"SPONSORED ADS","cusip":"07782B104","value":16938350,"shares":110000,"shareType":"SH","priorValue":18604097,"priorShares":116684},{"issuer":"COGENT BIOSCIENCES INC","titleOfClass":"COM","cusip":"19240Q201","value":16447500,"shares":425000,"shareType":"SH","priorValue":22940040,"priorShares":596000}],"positionsListed":23,"positions":[{"issuer":"ROIVANT SCIENCES LTD","titleOfClass":"SHS","cusip":"G76279101","value":283860642,"shares":8020928,"shareType":"SH","priorValue":226199502,"priorShares":8166047},{"issuer":"REVOLUTION MEDICINES INC","titleOfClass":"COM","cusip":"76155X100","value":51689280,"shares":276000,"shareType":"SH"},{"issuer":"MIRUM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"604749101","value":30496735,"shares":260500,"shareType":"SH","priorValue":21247400,"priorShares":230000},{"issuer":"ABIVAX SA","titleOfClass":"SPONSORED ADS","cusip":"00370M103","value":27518190,"shares":206500,"shareType":"SH","priorValue":13500631,"priorShares":121245},{"issuer":"BEONE MEDICINES LTD","titleOfClass":"SPONSORED ADS","cusip":"07725L102","value":25652999,"shares":90020,"shareType":"SH","priorValue":23918558,"priorShares":80542},{"issuer":"PHARVARIS N V","titleOfClass":"COM","cusip":"N69605108","value":23210407,"shares":671209,"shareType":"SH","priorValue":13927250,"priorShares":493000},{"issuer":"ARGENX SE","titleOfClass":"SPONSORED ADR","cusip":"04016X101","value":21338710,"shares":23000,"shareType":"SH","priorValue":26813320,"priorShares":36718},{"issuer":"UNITED THERAPEUTICS CORP DEL","titleOfClass":"COM","cusip":"91307C102","value":20112730,"shares":37120,"shareType":"SH"},{"issuer":"BELITE BIO INC","titleOfClass":"SPONSORED ADS","cusip":"07782B104","value":16938350,"shares":110000,"shareType":"SH","priorValue":18604097,"priorShares":116684},{"issuer":"COGENT BIOSCIENCES INC","titleOfClass":"COM","cusip":"19240Q201","value":16447500,"shares":425000,"shareType":"SH","priorValue":22940040,"priorShares":596000},{"issuer":"DBV TECHNOLOGIES S A","titleOfClass":"SPONSORED ADS","cusip":"23306J309","value":14915374,"shares":909474,"shareType":"SH","priorValue":14487925,"priorShares":693534},{"issuer":"XENON PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"98420N105","value":13279200,"shares":220000,"shareType":"SH","priorValue":13200050,"priorShares":227000},{"issuer":"BIONTECH SE","titleOfClass":"SPONSORED ADS","cusip":"09075V102","value":12508618,"shares":134429,"shareType":"SH"},{"issuer":"ARCUS BIOSCIENCES INC","titleOfClass":"COM","cusip":"03969F109","value":10969314,"shares":355800,"shareType":"SH","priorValue":4212000,"priorShares":195000},{"issuer":"ENLIVEN THERAPEUTICS INC","titleOfClass":"COM","cusip":"29337E102","value":10784375,"shares":212500,"shareType":"SH","priorValue":7840000,"priorShares":200000},{"issuer":"DIANTHUS THERAPEUTICS INC","titleOfClass":"COM","cusip":"252828108","value":10527840,"shares":108000,"shareType":"SH","priorValue":7878577,"priorShares":93882},{"issuer":"ALLOGENE THERAPEUTICS INC","titleOfClass":"COM","cusip":"019770106","value":10504000,"shares":5050000,"shareType":"SH","priorValue":8418000,"priorShares":3450000},{"issuer":"EYEPOINT INC","titleOfClass":"COM NEW","cusip":"30233G209","value":10296000,"shares":720000,"shareType":"SH","priorValue":10247550,"priorShares":795000},{"issuer":"ARCUTIS BIOTHERAPEUTICS INC","titleOfClass":"COM","cusip":"03969K108","value":9701400,"shares":370000,"shareType":"SH","priorValue":9439196,"priorShares":400645},{"issuer":"C4 THERAPEUTICS INC","titleOfClass":"COM STK","cusip":"12529R107","value":7513166,"shares":1608815,"shareType":"SH"},{"issuer":"INVENTIVA SA","titleOfClass":"ADS","cusip":"46124U107","value":7435906,"shares":1967171,"shareType":"SH"},{"issuer":"KYMERA THERAPEUTICS INC","titleOfClass":"COM","cusip":"501575104","value":5446825,"shares":47500,"shareType":"SH","priorValue":8329000,"priorShares":100000},{"issuer":"FAETH THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"81728A207","value":4376250,"shares":175050,"shareType":"SH"}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva Wealth is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}